Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025

Core Points - OSE Immunotherapeutics SA has published preparatory documents for its combined general meeting scheduled for June 25, 2025 [1] - The convening notice detailing the agenda and resolutions was published on May 21, 2025, with further publication scheduled for June 6, 2025 [2] - The Board of Directors emphasizes its commitment to good governance and long-term value creation for shareholders [3][13] Governance and Strategy - The Board invites shareholders to carefully consider the implications of the proposed resolutions, particularly those affecting the company's strategic stability [4] - Competing resolutions have been proposed by a group of shareholders holding approximately 24% of voting rights, which the Board believes could destabilize governance and disrupt strategy implementation [5][6] - The Board recommends voting against these competing resolutions, citing potential negative impacts on the company's governance and development trajectory [7] Shareholder Engagement - Registered shareholders can request relevant documents up to five calendar days before the General Meeting, with specific provisions for bearer form shareholders [9] - The company reaffirms its commitment to a fair and transparent general meeting process, ensuring respect for shareholder rights [10][12] - The Board is analyzing the completeness and timing of the competing resolutions proposed by the concerted shareholders [11]